David Adair

Dave Co-Founded Solas BioVentures based upon the desire to bring much needed innovation to the patient’s bedside. This patient centric focus came from his long academic medical career providing care and solutions to leverage the healthcare equation of Value = Quality /Cost. He has operated a startup MedTech, co-founded a large regional medical specialty group, as well as grown angel investing into a full fledge venture fund targeting MedTech, pharma, diagnostics, and special healthcare situations. Dave was the Southeast Medical Device Association member of the year in 2017. He has served on Life Science Tennessee Association Board previously. He is a widely published author with over 100 articles and a frequent speaker to academic venues throughout the U.S. and E.U. He retired as professor emeritus from the University of Tennessee College of Medicine in the Department of Obstetrics and Gynecology. His prior board experience is notable for Veran Medical acquired by Olympus Medical, NxThera acquired by Boston Scientific, Aegea Medical acquired by Cooper Surgical, and Aerial BioPharma acquired by Jazz Pharmaceuticals. Besides serving on the board of Arrivo BioPharma he serves on Veranex Solutions, Francis Medical, Knopp BioSciences, Intershunt Technologies, and Vesalio.

Dave earned a BS in Biology from Morehead State University, a MD from The Joan C Edwards School of Medicine of Marshall University, Residency in Obstetrics & Gynecology from The University of Florida, Maternal Fetal Medicine from Wake Forest University, and an MBA from The Gary W. Rollins College of Business of The University of Tennessee Chattanooga.